Latest Period
Q1 2026
CUSIP: 64049MAB6
Latest Period
Q1 2026
Institutions Reporting
21
Principal
$344,881,000
Price (% of par)
91.5%
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
Latest holder context comes from 21 institutions filings for Q1 2026.
Security key
64049MAB6
Latest holder period
Q1 2026
13F holders
21
13D/G owners
0
CIK / CUSIP context first
Broader feeds
Open recent reporting periods for CUSIP 64049MAB6:
As of 31 Mar 2026, 21 institutional investors reported holding $344,881,000 in principal (par value) of NEOGENOMICS INC - NOTE 0.250% 1/1.
Quarter history
Holder count, reported shares/value, and median price by quarter.
| Period | Principal | Value | Change | Price (% of par) (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | $344,881,000 | $317,337,315 | -$626,840 | 91.5% | 21 |
| 2025 Q4 | $346,175,000 | $310,349,378 | +$981,480 | 89.26% | 21 |
| 2025 Q3 | $345,063,000 | $300,247,353 | -$1,047,258 | 86.5% | 21 |
| 2025 Q2 | $347,424,500 | $298,701,017 | +$1,329,076 | 85.38% | 24 |
| 2025 Q1 | $345,968,500 | $300,355,654 | +$507,793 | 86.32% | 24 |
| 2024 Q4 | $346,156,500 | $292,693,370 | -$7,990,591 | 84.0% | 27 |
| 2024 Q3 | $356,060,500 | $296,374,577 | +$17,437,220 | 82.86% | 28 |
| 2024 Q2 | $335,580,500 | $263,497,607 | +$1,308,070 | 78.17% | 28 |
| 2024 Q1 | $333,774,500 | $266,976,531 | +$1,456,937 | 79.75% | 25 |
| 2023 Q4 | $333,400,500 | $253,694,214 | +$3,165,777 | 75.6% | 30 |
| 2023 Q3 | $329,987,000 | $237,042,492 | -$556,393 | 71.53% | 28 |
| 2023 Q2 | $330,413,000 | $243,310,105 | -$296,237 | 73.32% | 32 |
| 2023 Q1 | $330,802,000 | $244,199,793 | +$1,969,797 | 73.51% | 30 |
| 2022 Q4 | $331,631,000 | $215,226,340 | +$776,251 | 64.63% | 33 |
| 2022 Q3 | $277,556,500 | $183,092,769 | -$26,084,301 | 64.64% | 31 |
| 2022 Q2 | $318,858,347 | $202,728,341 | +$10,098,000 | 62.13% | 30 |
| 2022 Q1 | $298,643,089 | $201,340,104 | -$2,525,738 | 66.57% | 36 |
| 2021 Q4 | $293,181,906 | $250,805,827 | -$23,948,051 | 85.41% | 31 |
| 2021 Q3 | $320,195,500 | $323,656,284 | +$11,107,101 | 101.13% | 33 |
| 2021 Q2 | $308,715,774 | $302,787,253 | +$10,622,528 | 97.62% | 29 |
| 2021 Q1 | $298,991,370 | $302,575,255 | +$302,575,255 | 101.11% | 38 |